2007, Number 1
<< Back Next >>
Rev Biomed 2007; 18 (1)
Benign prostate pathologies: prostatitis and benign prostatic hyperplasia
Rodríguez-López MR, Baluja-Conde IB, Bermúdez-Velásquez S
Language: Spanish
References: 57
Page: 47-59
PDF size: 390.98 Kb.
ABSTRACT
An analysis of the prostate anatomy, as well as of the most relevant factors that regulate prostatic growth and of the gland functions that might influence the etiology of different prostate pathologies, is carried out in this work. Several benign prostate pathologies are studied in this article, emphasizing prostatitis and benign prostate hyperplasia (BPH). Key parameters in the early diagnosis of these disorders and their treatments are also analyzed.
The term prostatitis includes a group of symptoms and functional disorders that affect the prostate. It is the most frequent genitourinary infection in men between the second and forth decades of life. There are different types of prostatitis, each having its own origin, clinical presentation and specific treatment.
BPH is a disease that affects between 50 and 80% of men over 50 years old. A sustained growth of the prostate progressively leads to urinary retention, renal dysfunction, and infection. Differentiating symptomatology according to its “irritative” characteristics (dynamic component) or “obstructive characteristics” (static component) will guide the application of an individualized and specific pharmacological treatment (alphablockers-hormone therapy), with the objective of lessening the symptoms and improving the patient’s quality of life.
REFERENCES
Aumüller, G. Prostate gland and seminal vesicles. Springer-Verlag Berlin-Heidelberg. 1979.
Luke MC, Coffey DS. The male sex accesory tissues. In: The physiology of reproduction; Knobil E, Nelly J. (eds.) New York: Raven Press Ltd; 1994. p. 1435-87.
Torrubia FJ. Cruz N. Pascual JL. Factores de crecimiento e hiperplasia benigna de próstata. Hiperplasia benigna de próstata y medicina basada en la evidencia. Revista Clínica Española 1999; 199:19-23.
Cunha G, wang Y, Hayward S, Risbridger G. Estrogenic effects on prostatic differentiation and carcinogenesis. Reprod Fertile Dev 2001; 13:285-96.
Barañao JLS, Calvo JC, Luthy IA, González SI, Charreau EH, Calandra RS. Prolactin effects on prepubertad male rat. En Recent Advances in Male Reproduction: Molecular Bases and Clinical Implications. R D´Agata, MB Lipsett, P polosa, MJ van der Molen (editores) New Cork: Raven Press; 1983. Vol. 7, p. 305-12.
Costello LC, Franklin RB. Effects of prolactin on the prostate. Prostate 1994; 24:162-6.
Nevalainen MT, Valve E, Ingleton P, Nurmi M, Martikainen P, Harkonen P. Prolactin and prolactin receptors are expressed and functioning in human prostate. J Clin Invest 1997; 99:618-27.
Reiter E, Hennuy B, Bruyninx M, Cornet A, Klung M, McNamara M, et al. Effects of pituitary hormones on the prostate. Prostate 1999; 38:159-65.
Hammond G, Kontturi M, Manttala P, Puukka M, Vihko R. Serum FSH, LH and prolactin in normal males and patients with prostatic diseases. Clin Endocrinol 1977; 7:129-37.
Nevalainen MT, Valve E, Ahonen T, Yagi A, Paranko J, Harkonen P. Androgen-dependent expression of prolactin in rat prostate epithelium in vivo and in organ culture. FASEB J 1997; 11:1297-307.
Prins G. Prolactin influence of cytosol and nuclear androgen receptors in the ventral, dorsal and lateral lobes in the rat postate. Endocrinology 1987; 120:1457-64.
Naber KG. Complicated urinary tract infections. Lectures in hospital infections. Sciences Press Communications 2003; 1-43.
Francolugo Vélez VA. Prostatitis, un reto para el urólogo. Urología Panamericana. 2003; 15:31-4.
Clinical Effectiveness group (Association for Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases). 2001 National Guideline for the Management of Prostatitis (En Línea) (Fecha de consulta: Julio 2006). Disponible en: www.bassh.org/guidelines/2002/prostatitis-0601.pdf
Anónimo. Prostatitis. Medicina General 2000; 27:754-58.
Hervás A, Forcén T. Prostatitis. Guías Clínicas 2002; 2(40).
Meyrier A, Fekete T. Prostatitis sindromes. UpToDate (versión 10.3) (En Línea). Fecha de consulta (julio 2006). Disponible en: www.fisterra.com/guías2/PDF PDF/Protatitis.pdf
Krieger J. Chronic prostatitis epidemiology and role of infection. Urology 2002; 60 (Suppl 6A): 8-13.
Naber KG, Bergman B, Bishop MC, Bjerklund-Johansen TE, Botto H, Lobel B et al. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). Eur Urol 2001 Nov; 40:576-88.
McMaughton M, MacDonald R, Kilt J. Interventions for chronic abacterial prostatitis. The Cochrane Library, Issue 3, 2002. Oxford: Update Software Ltd.
Saladié JM, Areal J, Cecchini L, Comet J, Escalera C, Ibarz L, Uria J. Conocimientos prácticos sobre Hipertrofia benigna de próstata. Barcelona: Ediciones Mayo. 1998.
Burgos Rodríguez R, Chicharro Molero JA. Hiperplasia benigna de próstata. En: Jiménez Cruz JF, Rioja Sanz LA. Tratado de Urología. Barcelona: Ed. J.R. Proas; 1993. p. 1035-50.
Resel Let al. Hiperplasia Benigna de Próstata. Bases diagnósticas y terapéuticas. Madrid: Ed. Enar; 1993.
Marcelli M, Cunnigjam GR. Hormonal signaling in prostatic hyperplasia and neoplasia. J Clin Endoc Metab 1999; 84:3463-8.
Tunn S, Nass R, Ekkernkamp A, Schulze H, Krieg M. Evaluation of average life span of epithelial and stromal cells of human prostate by superoxide dismutase activity. Prostate 1989; 15:263-71.
Ball EMA, Risbridger GP. New perspectives on growth factor-steroid interaction in the prostate. Cyt Growth Fact Rev 2003; 14:5-16.
Eaton CL. Aetiology and pathogenesis of benign prostatic hyperplasia. Curr Opin Urol 2003; 13:7-10.
Lepor, Lawson. Enfermedades de la próstata. Buenos Aires: Ed. Panamericana; 1994.
Hernández C, Moncada I. Hiperplasia benigna de próstata. Madrid: Ed. Luzán; 1999.
Position of the American Dietetic Association and Dieticians of Canada. Vegetarian diets. Journal Am Diet Assoc 2003; 748-65.
Hammarsten J, Hogstedt B. La hiperinsulinemia como factor de riesgo de la hiperplasia benigna de prostática. Eur Urol 2002 (ed esp); IX:28-35.
Algaba F, Trías I, López L, Rodríguez-Vallejo J M, González J. Evolución morfológica de la hiperplasia de próstata. Actas Urol Esp 2000; 463-7.
González SI, Salcedo JL, Martínez MA. Últimos avances en el diagnóstico de la hiperplasia benigna de próstata. Acta Bioquim Clin Latinoam 2005; 39:171-85.
Carballido JA, Rodríguez J, Llano J. Hiperplasia prostática benigna y medicina basada en la evidencia. Med Clin (Bar) 2000;114(Suppl 2):96-104.
Gómez Acebo A, Rodríguez Vallejo JM, Rodríguez Mora VI, García Alcálzar I. Quality of life and symptomatology in benign prostate hyperplasia in active spanish population. Med Clin 2000;114 (Suppl 3):81-9.
Vela-Navarrete R, Alfaro V, Badiella LL, Fernández HN. Age-stratified analysis of IPSS and QoL: values in Spanish patients with symptoms potentially related to BPH. Eur Urol 2000; 38:199-207.
Brenes FJ, Milozzi J. Síndrome prostático (hiperplasia benigna de próstata). En: Brenes FJ, Ibarz L. “Urología 2000 APS”. Programa de Formación SEMERGEN (Casos clínicos de referencia en atención primaria). 1ª Unidad Didáctica. Madrid: Meditex; 2000. p. 9-23.
Brenes FJ, Ródenas JL. HTA y síndrome prostático con retención aguda de orina. En: Brenes FJ, Romero R. Casos clínicos de hipertensión Arterial asociada a Síndrome Prostático. Programa de Formación 2001. 1a Unidad Didáctica. Madrid: Meditex; 2001. p. 35-40.
Salinas Sánchez AS, Hernández Millán IR, Segura Martín M, Lorenzo Romero JG, López Torres Hidalgo J, Virseda Rodríguez JA. Impact of prostatic symptoms in patients with prostatic benign hyperplasia. Arch Esp Urol 2000; 53:212-24.
Barry MJ, Wiiliford WO, Fowler FJ. American Urological Association Symptom index: The value of their distinction in a Veterans Affairs randomised trial of medical therapy in men with a clinical diagnosis of benign prostatic hyperplasia. J Urol 2000; 164:1559-64.
Chicharro Molero JA, Burgos Rodríguez R. Epidemiology of benign prostatic hyperplasia. Definition of the condition. Rev Clin Española 1999; 199(Suppl 2): 12-18.
Arlandis S, Jiménez F. Rentabilidad de las distintas pruebas diagnósticas en el estudio de la hiperplasia benigna de próstata. Hiperplasia benigna de próstata y medicina basada en la evidencia. Revista Clínica Española 1999; 199:36-43.
Rodríguez Mora VL, Rodríguez Vallejo JM, GarcíaAlcázar I, Gómez Acebo A. Benign prostatic hyperplasia: measurement of symptoms, IPSS and life quality assessment. Rev Clin Esp 1999; 199 (Suppl 2):30-5.
de la Rossette JJMCH, Deric KE, van der Schoot DKE, Debruyne FMJ. Recents develoments in guidelines on benign prostatic hyperplasia. Curr Op Urol 2002; 12:3-6.
Castro Díaz D, Postius Robert J. Urología en AP. Barcelona: Ed. Pulso; 2001.
Laguna P, Alivizatos G. Antígeno prostático específico e hiperplasia prostática benigna. Curr Op Urol 2000; 10:3-8.
Postius J, Castro D. Tratamiento farmacológico de la HBP basado en la evidencia. Re Clin Esp 1999; 199:58-61.
Moncada I, Leal F, Jara J, de Palacio A, Hernández C. Tratamiento farmacológico de la hiperplasia benigna de próstata. En: Astobieta A, Rodríguez-Sasiain JM, Resel L. Tratado de farmacoterapia en urología. Madrid: Ediciones Luzán;2000. p. 651-76.
Berges RR, Windeler J, Trampisch HJ, SengeT. Randomised, placebo-controlled, double bind clinical trial of betasitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group. Lancet 1995; 1529-32.
Vergeles-Blanca JM, Pozuelos G, Buitrago F. Controversias en el tratamiento de la hiperplasia benigna de próstata. FMC-Formación Médica Continuada en Atención Primaria. 1996. p. 215.
Wilt TJ, Ishani A, Stark G, MacDonald R, Mulrow C, Sau J. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2000; 2:CD001423.
Lepor H. The treatment of benign prostatic hyperplasia with alpha-blockers. Curr Op Urol 1994; 4:16-21.
Abrams P, Schulman CC, Vaage S. European Tamsulosim Study Group. Tamsulosin a selective alpha-1c adrenoreceptor antagonist. Br J Urol 1995; 76: 325.
McConnell JD for the PLESS Study Group. The longterm effects of finasteride on BPH: results of a four-year, placebo controlled study. Br J Urol 1997; 80 (Suppl 2): 182.
Mc Connell JD, Bruskwitz R, Walsh P, Adriole G, Liebre M, Holtgrewe L, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Eng J Med 1998; 338:557-63.
Mebust WK. Selection of the surgical procedure for management of benign prostatic hyperplasia. Prog Clin Biol Res 1994; 386:369-84.
Valle Blasco M. García Timón A, Muñoz V. Abordaje de l hiperplasia benigna de próstata. MEDIFAM 2003; 13: 133-42.